Inclusion Criteria:

- Recurrent malignant glioma with radiographic progression

- No more than three prior therapies.

- Male or female patients >=18 years old

- KPS >=60.

- Ability to provide written informed consent or consent obtained from responsible
healthcare proxy.

- Contrast-enhanced MRI within 2 weeks of enrollment.

- Life expectancy >= 8 weeks

- Neutrophils >1500/mm3

- Platelets > 100,000/mm3L

- Hemoglobin >=9 g/dL

- AST/SGOT and ALT/SGPT <= 2.5 x upper limit of normal (ULN) or < 5.0 x ULN if the
transaminase elevation is due to disease involvement

- Serum bilirubin <= 1.5 x ULN

- Serum creatinine <= 1.5 x ULN or 24-hour creatinine clearance >= 50 ml/min

- Total serum calcium or ionized calcium WNL

- Serum potassium WNL

- Serum sodium WNL

- Serum albumin >= LLN or 3g/dl

- Elevated Alkaline Phosphatase due to bone metastasis can be enrolled

- Baseline MUGA or ECHO must demonstrate LVEF >= the LLN

- TSH and free T4 WNL (patients may be on thyroid hormone replacement)

- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
within 7 days of the first administration of study treatment and must be willing to
use two methods of contraception one of them being a barrier method during the study
and for 3 months after last study drug administration.

- No concurrent antitumor therapy.

- No enzyme-inducing antiepileptic drugs.

- No significant comorbidities

- Patients must have recovered from toxic effects of prior therapy.

Exclusion criteria

- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

- Valproic acid for any medical condition during the study or within 5 days prior to
first LBH589 treatment

- Impaired cardiac function including:

- Screening ECG with a QTc > 450 msec

- Congenital long QT syndrome

- History of sustained ventricular tachycardia

- History of ventricular fibrillation or torsades de pointes

- Bradycardia < 50 beats per minute. Patients with a pacemaker and heart rate > = 50
beats per minute are eligible.

- Myocardial infarction or unstable angina within 6 months

- Congestive heart failure (NYHA class III or IV)

- RBBB and LAH (bifascicular block)

- Uncontrolled hypertension

- Concomitant use of drugs with a risk of causing torsades de pointes Concomitant use
of CYP3A4 inhibitors

- Patients with unresolved diarrhea

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter absorption of LBH589

- Concurrent severe and/or uncontrolled medical conditions

- Chemotherapy, any investigational drug or major surgery < 4 weeks prior to starting
study drug or have not recovered from side effects of such therapy.

- Concomitant use of any anti-cancer therapy or radiation therapy.

- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
not willing to use a double barrier method of contraception during the study and 3
months after the end of treatment. One of these methods of contraception must be a
barrier method.

- Male patients whose sexual partners are WOCBP not using a double method of
contraception during the study and 3 months after the end of treatment. One of these
methods must be a condom

- History of another primary malignancy within 5 years other than curatively treated
CIS of the cervix, or basal or squamous cell carcinoma of the skin

- Known human immunodeficiency virus (HIV) or hepatitis C positivity

- Significant history of non-compliance to medical regimens or inability to grant a
reliable informed consent

- More than three prior therapies

- Hepatic or renal diseases or any diseases that will obscure toxicity or alter drug
metabolism

- Known active malignancies

- Active infection requiring iv antibiotics

- Systemic anticoagulants

- Enzyme-inducing antiepileptic drugs